Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma
Sign Up to like & getrecommendations! Published in 2018 at "Melanoma Research"
DOI: 10.1097/cmr.0000000000000399
Abstract: Talimogene laherparepvec is a genetically modified herpes simplex virus-1-based oncolytic immunotherapy for the local treatment of unresectable cutaneous, subcutaneous, and nodal tumors in patients with melanoma recurrence following surgery. We aim to describe the safety… read more here.
Keywords: stage iiib; talimogene laherparepvec; treatment; safety ... See more keywords
Talimogene laherparepvec can initiate plasma cell invasion into infiltrated melanoma lesions – a case series
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.16922
Abstract: Talimogene laherparepvec (T-VEC) is a genetically engineered herpes simplex virus type 1 (HSV-1) and used in locally advanced melanoma patients. Its mode of action is not fully understood. We present three cases where T-VEC caused… read more here.
Keywords: laherparepvec initiate; talimogene laherparepvec; plasma cell; initiate plasma ... See more keywords
Pharmacy Operationalization of the Intralesional Oncolytic Immunotherapy Talimogene Laherparepvec
Sign Up to like & getrecommendations! Published in 2018 at "Hospital Pharmacy"
DOI: 10.1177/0018578717749926
Abstract: Objective: Oncolytic immunotherapy involves the use of viruses to target and destroy cancer cells and to induce immune responses for an enhanced antitumor effect. Talimogene laherparepvec, a genetically modified herpes simplex virus type 1 (HSV-1)… read more here.
Keywords: talimogene; talimogene laherparepvec; pharmacy operationalization; oncolytic immunotherapy ... See more keywords
Clinical experience with talimogene laherparepvec in a melanoma population at a university based cancer center.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e21547
Abstract: e21547Background: Talimogene laherparepvec (Imlygic or T-VEC) is a first-in-class oncolytic virus that received FDA approval for recurrent unresectable melanoma based on the OPTiM trial. Since its ... read more here.
Keywords: talimogene laherparepvec; experience talimogene; talimogene; clinical experience ... See more keywords